Obesity treatment: WHO guideline on the use of GLP-1 therapies
The World Health Organization has released its first global guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity, recognising the condition as a chronic and relapsing disease. The move comes amid rising global demand for GLP-1 medications—such as semaglutide and liraglutide—currently used for diabetes and weight management. Here’s what the new guidance means and why it matters.
What are GLP-1 therapies?
GLP-1 therapies (glucagon-like peptide-1 receptor agonists) are medications that mimic the body’s natural GLP-1 hormone, which regulates blood sugar and appetite. Originally developed to manage type-2 diabetes, these drugs are now widely used for weight loss and obesity treatment.
Beyond weight management, some GLP-1 medicines have shown additional benef...










